MedTrace Logo

Safety and Tolerability Evaluation of Akkermansia Muciniphila

NCT06728098 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 108

Last updated 2025-07-29

No results posted yet for this study

Summary

This is a randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of Akkermansia muciniphila Akk11 in healthy adult.

Conditions

  • Healthy

Interventions

DIETARY_SUPPLEMENT

Probiotic

The experimental phase of this study had last 30 days and each patient will make 3 visits (d1,d15,d30).

DIETARY_SUPPLEMENT

Maltodextrin

The experimental phase of this study had last 30 days and each patient will make 3 visits (d1,d15,d30).

Sponsors & Collaborators

  • Wecare Probiotics Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-11-25
Primary Completion
2025-12-25
Completion
2026-03-25

Countries

  • Indonesia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06728098 on ClinicalTrials.gov